<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805177</url>
  </required_header>
  <id_info>
    <org_study_id>2021-00161, ko21Bonati</org_study_id>
    <nct_id>NCT04805177</nct_id>
  </id_info>
  <brief_title>Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage</brief_title>
  <official_title>Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage: a Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Swiss Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Basel, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this pilot study is to provide an assessment of safety and feasibility of early&#xD;
      minimally invasive image guided endoscopic hematoma evacuation (within 24 hours of symptom&#xD;
      onset) in patients suffering from intracerebral haemorrhage (ICH).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Spontaneous supratentorial intracerebral haemorrhage (SSICH) is the is the second most common&#xD;
      form of stroke. The aim of this single centre, single arm pilot study is to provide an&#xD;
      assessment of safety and feasibility of early minimally invasive image guided endoscopic&#xD;
      hematoma evacuation (within 24 hours of symptom onset) in patients suffering from&#xD;
      intracerebral haemorrhage (ICH).&#xD;
&#xD;
      Furthermore this study contributes to the understanding of secondary neuronal damage involved&#xD;
      in ICH through the measurement of biomarkers for neuronal damage and their response to early&#xD;
      hematoma evacuation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>single arm pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Level of disability</measure>
    <time_frame>6 month after treatment onset</time_frame>
    <description>level of disability 6 months after treatment, measured by the modified Rankin Scale (mRS). Good functional outcome is defined by a score on the mRS of ≤3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hematoma volume to ≤15 mL</measure>
    <time_frame>from baseline to 24 hours after treatment</time_frame>
    <description>Change in hematoma volume to ≤15 mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of specific adverse events (AE)</measure>
    <time_frame>6 month after treatment onset</time_frame>
    <description>number of specific adverse events (AE) (death, ischemic stroke, recurrent ICH (defined as any increase in hematoma volume at follow-up that is associated with a worsening of the focal-neurological deficit by ≥4 points on the National Institute of Health Stroke Scale (NIHSS) and/or a decrease in consciousness by ≥2 points on the Glasgow Coma Scale (GCS), epileptic seizure, infection, any need for open neurosurgical procedures)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in relative (percentage) hematoma volume</measure>
    <time_frame>from baseline to 24 hours after treatment</time_frame>
    <description>Change in relative (percentage) hematoma volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of focal neurological deficit measured by the NIHSS</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>Change of focal neurological deficit measured by the NIHSS. The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of serum biomarkers of brain injury</measure>
    <time_frame>from baseline to 6 months</time_frame>
    <description>Change of serum biomarkers of brain injury (light-chain neurofilament subunit (NfL), the Glial Fibrillary Acidic Protein (GFAP) and the S100 calcium-binding protein B (S100B))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time spent on the intensive care unit</measure>
    <time_frame>from baseline to hospital discharge (approx. 1 month)</time_frame>
    <description>Total time spent on the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total time spent in intubation</measure>
    <time_frame>from baseline to hospital discharge (approx. 1 month)</time_frame>
    <description>Total time spent in intubation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Intracerebral Hemorrhage (ICH)</condition>
  <arm_group>
    <arm_group_label>hematoma evacuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early minimally invasive image guided hematoma evacuation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hematoma evacuation</intervention_name>
    <description>early minimally invasive image guided hematoma evacuation in patients suffering from ICH</description>
    <arm_group_label>hematoma evacuation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No relevant disability prior to ICH (mRS 0-1 prior to ICH)&#xD;
&#xD;
          -  Primary supratentorial deep or superficial intraparenchymal ICH of volume ≥ 20 mL &lt;&#xD;
             100 mL (measured using formula) demonstrated on CT or MRI, with or without a 2&#xD;
             component of intraventricular haemorrhage&#xD;
&#xD;
          -  CT/MRI demonstrates ICH stability (&lt; 5 mL growth) at 6 hours after the admission scan&#xD;
             if surgery is performed &gt;6 hours after admission CT&#xD;
&#xD;
          -  NIHSS ≥ 10&#xD;
&#xD;
          -  Presenting GCS 5 - 15&#xD;
&#xD;
          -  Endoscopic haematoma evacuation can be initiated within 24 hours of symptom onset&#xD;
&#xD;
          -  Systolic blood pressure can be controlled at &lt;160 mmHg&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Imaging:&#xD;
&#xD;
               -  &quot;Spot sign&quot; identified on CT angiography (CTA)&#xD;
&#xD;
               -  Structural vascular or brain lesion as suspected cause of ICH, such as a vascular&#xD;
                  malformation (cavernous malformation, arteriovenous malformation (AVM) etc),&#xD;
                  aneurysm, neoplasm&#xD;
&#xD;
               -  Haemorrhagic conversion of an underlying ischemic stroke&#xD;
&#xD;
               -  Infratentorial haemorrhage&#xD;
&#xD;
               -  Large associated intra-ventricular haemorrhage requiring treatment for related&#xD;
                  mass effect or shift due to trapped ventricle (extraventricular drainage (EVD)&#xD;
                  for intracranial pressure (ICP) management is allowed)&#xD;
&#xD;
               -  Midbrain extension/involvement&#xD;
&#xD;
          -  Coagulation Issues:&#xD;
&#xD;
               -  Oral or parenteral therapeutic anticoagulation at time of ICH onset&#xD;
&#xD;
               -  Absolute requirement for long-term anti-coagulation (e.g., Mechanical valve&#xD;
                  replacement (bio-prostatic valve is permitted), high risk atrial fibrillation)&#xD;
&#xD;
               -  Known hereditary or acquired haemorrhagic diathesis, coagulation factor&#xD;
                  deficiency&#xD;
&#xD;
               -  Platelet count &lt; 100 x 103 cells/mm3 or known platelet dysfunction&#xD;
&#xD;
               -  international normalized ratio (INR) &gt; 1.5 for any reason, elevated prothrombin&#xD;
                  time or activated partial thromboplastin time (aPTT), which cannot be corrected&#xD;
                  or otherwise accounted for (i.e., lupus anti-coagulant)&#xD;
&#xD;
          -  Presenting GCS 3 or 4&#xD;
&#xD;
          -  Requirement for emergent surgical decompression or uncontrolled ICP after EVD&#xD;
&#xD;
          -  Unable to obtain consent from patient or appropriate surrogate (for patients without&#xD;
             competence)&#xD;
&#xD;
          -  Pregnancy, breast-feeding, or positive pregnancy test [either serum or urine] (woman&#xD;
             of child-bearing potential must have a negative history of current pregnancy prior to&#xD;
             the study procedure)&#xD;
&#xD;
          -  Evidence of active infection (indicated by fever ≥38°C) at the time of study inclusion&#xD;
&#xD;
          -  Any comorbid disease or condition expected to compromise survival or ability to&#xD;
             complete follow-up assessments through 180 days&#xD;
&#xD;
          -  Based on physician's judgment, patient does not have the necessary mental capacity to&#xD;
             participate or is unwilling or unable to comply with protocol follow up appointment&#xD;
             schedule&#xD;
&#xD;
          -  Active drug or alcohol use or dependence&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leo Bonati, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Basel, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leo Bonati, Prof.Dr.med.</last_name>
    <phone>+41 61 556 5442</phone>
    <email>leo.bonati@usb.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jehuda Soleman, PD Dr.med.</last_name>
    <phone>+41 61 328 6076</phone>
    <email>jehuda.soleman@usb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Bonati, Prof. Dr. med.</last_name>
      <email>Leo.bonati@usb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery, University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jehuda Soleman, PD. Dr. med.</last_name>
      <email>Jehuda.soleman@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Jehuda Soleman, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endoscopic evacuation</keyword>
  <keyword>pilot study</keyword>
  <keyword>spontaneous supratentorial Intracerebral Hemorrhage (SSICH)</keyword>
  <keyword>minimally invasive image guided endoscopic surgery</keyword>
  <keyword>early hematoma evacuation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

